| Product Name |
Acadesine - API
|
| Product Code |
DA-A012-01
|
| Chemical name |
Acadesine
|
| Synonyms |
5-Amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-imidazole-4-carboxamide; Imidazole-4-carboxamide, 5-amino-1-β-D-ribofuranosyl; 1-β-D-Ribofuranosyl-5-amino-4-imidazolecarboxamide; 5-Amino-1-ribosyl-4-imidazolecarboxamide; 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; AICAR; Acadesine; 5-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide; 5-Amino-4-imidazole carboxamide Riboside; Arasine; GP 1-110;
|
| Impurity |
NA
|
| CAS Number |
2627-69-2
|
| Alternate CAS # |
NA
|
| Molecular form |
C9H14N4O5
|
| Appearance |
Off-White to Pale Beige Solid
|
| Melting Point |
NA
|
| Mol. Weight |
258.23
|
| Storage |
2-8°C Refrigerator
|
| Solubility |
NA
|
| Stability |
NA
|
| Category |
bases and related reagents,nucleotides,carbohydrates
|
| Boiling Point |
NA
|
| Applications |
Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
|
| Dangerous Goods Info |
NA
|
| References |
NA
|
| Extra Notes |
NA
|
| Documents (MSDS) |
No Data Available
|
| Keywords |
NA |
